Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation-Reference-Cited by-同舟云学术

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Published:2013-10 Issue: Volume:248 Page:451-456
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Rozenstein-Tsalkovich Lea,Grigoriadis Nikolaos,Lourbopoulos Athanasios,Nousiopoulou Evangelia,Kassis Ibrahim,Abramsky Oded,Karussis Dimitrios,Rosenmann Hanna

Funder

Chief Scientist Office of the Ministry of Health, Israel

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference21 articles.

1. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements;Asuni;J. Neurosci.,2007

2. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?;Banks;Curr. Pharm. Des.,2004

3. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice;Bi;PLoS One,2011

4. Mild experimental autoimmune encephalitis as a tool to induce blood–brain barrier dysfunction;Boettger;J Neural Transm,2010

5. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice;Boimel;Exp. Neurol.,2010

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tau-Targeted Immunotherapy for Alzheimer's Disease: Insight into Clinical Trials;OBM Neurobiology;2024-08-07

2. Tau-targeting therapies for Alzheimer disease: current status and future directions;Nature Reviews Neurology;2023-10-24

3. Role of neuroinflammation in neurodegeneration development;Signal Transduction and Targeted Therapy;2023-07-12

4. Active immunotherapy against pathogenic Cis pT231-tau suppresses neurodegeneration in traumatic brain injury mouse models;Neuropeptides;2022-12

5. Investigational therapeutics for the treatment of progressive supranuclear palsy;Expert Opinion on Investigational Drugs;2022-06-13